Enhanced Effectiveness of Radiochemotherapy with Tirapazamine by Local Application of Electric Pulses to Tumors

Abstract Maxim, P. G., Carson, J. J. L., Ning, S., Knox, S. J., Boyer, A. L., Hsu, C. P., Benaron, D. A. and Walleczek, J. Enhanced Effectiveness of Radiochemotherapy with Tirapazamine by Local Application of Electric Pulses to Tumors. Radiat. Res. 162, 185–193 (2004). Tumor hypoxia is associated with resistance to radiotherapy and anticancer chemotherapy. However, it can be exploited to therapeutic advantage by concomitantly using hypoxic cytotoxins, such as tirapazamine (TPZ). Tumor electroporation offers the means to further increase tumor hypoxia by temporarily reducing tumor blood flow and therefore increase the cytotoxicity of TPZ. The primary objective of this work was to determine whether electric pulses combined with TPZ and radiotherapy (electroradiochemotherapy) was more efficacious than radiochemotherapy (TPZ + radiation). In these studies using the SCCVII tumor model in C3H mice, electroradiochemotherapy produced up to sixfold more tumor growth delay (TGD) than TPZ + radiation. In these studies, (1) large tumors (280 ± 15 mm3) responded better to electroradiochemotherapy than small tumors (110 ± 10 mm3), (2) TGD correlated linearly with tumor volume at the time of electroradiochemotherapy, (3) electric pulses induced a rapid but reversible reduction in O2 saturation, and (4) the electric field was highest near the periphery of the tumor in a 3D computer model. The findings suggested that electroradiochemotherapy gained its therapeutic advantage over TPZ + radiation by enhancing the cytotoxic action of TPZ through reduced tumor oxygenation. The greater antitumor effect achieved in large tumors may be related to tumor morphology and the electric-field distribution. These results suggest that electro-pulsation of large solid tumors may be of benefit to patients treated with radiation in combination with agents that kill hypoxic cells.

[1]  J. Evans,et al.  Metabolism of tirapazamine by multiple reductases in the nucleus. , 2001, Biochemical pharmacology.

[2]  L. H. Gray,et al.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.

[3]  M. Kris,et al.  Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M Cemazar,et al.  Tumour blood flow changes induced by application of electric pulses. , 1999, European journal of cancer.

[5]  M. Lemmon,et al.  Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Damijan Miklavčič,et al.  Changing electrode orientation improves the efficacy of electrochemotherapy of solid tumors in mice , 1996 .

[7]  S. Orlowski,et al.  Electrochemotherapy on liver tumours in rabbits. , 1998, British Journal of Cancer.

[8]  M Cemazar,et al.  Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin , 2002, British Journal of Cancer.

[9]  D. Hirst,et al.  Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. , 1983, Cancer research.

[10]  E. Neumann,et al.  Electroporation and Electrofusion in Cell Biology , 1989, Springer US.

[11]  S. Spencer,et al.  Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. , 1998, International journal of radiation oncology, biology, physics.

[12]  M. Lemmon,et al.  SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. , 1986, International journal of radiation oncology, biology, physics.

[13]  D Miklavcic,et al.  Calculation of the electrical parameters in electrochemotherapy of solid tumours in mice , 1998, Comput. Biol. Medicine.

[14]  H. Thames,et al.  Tumor volume: a basic and specific response predictor in radiotherapy. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  J. Weaver.  Molecular basis for cell membrane electroporation. , 1994, Annals of the New York Academy of Sciences.

[16]  C. Coleman,et al.  Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. , 1994, International journal of radiation oncology, biology, physics.

[17]  C. Coleman,et al.  Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. , 1999, International journal of radiation oncology, biology, physics.

[18]  D. Dunlop,et al.  Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Lambin,et al.  Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. , 2000, European journal of cancer.

[20]  D. Chang,et al.  Guide to Electroporation and Electrofusion , 1991 .

[21]  Torben Skovsgaard,et al.  Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. , 2002, Biochimica et biophysica acta.

[22]  C. Haie-meder,et al.  Tumour size in cancer of the cervix. , 1998, Acta oncologica.

[23]  Richard Heller,et al.  Electrochemotherapy, electrogenetherapy, and transdermal drug delivery : electrically mediated delivery of molecules to cells , 2000 .

[24]  E. Neumann,et al.  Electro-optics of membrane electroporation in diphenylhexatriene-doped lipid bilayer vesicles. , 1996, Biophysical chemistry.

[25]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[26]  L. Mir,et al.  Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. , 1991, European journal of cancer.

[27]  David K. Stevenson,et al.  Noninvasive Methods for Estimating In Vivo Oxygenation , 1992, Clinical pediatrics.

[28]  J. Brown,et al.  Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. , 1992, Cancer research.

[29]  A. E. van den Berg-Blok,et al.  Differential heat sensitivity of tumour microvasculature. , 1990, European journal of cancer.

[30]  J. Denekamp,et al.  Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. , 1989, European journal of cancer & clinical oncology.

[31]  M Cemazar,et al.  Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. , 2000, International journal of radiation oncology, biology, physics.

[32]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[33]  J. Brown,et al.  Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. , 1998, Cancer research.

[34]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[35]  M. Okino,et al.  Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. , 1987, Japanese journal of cancer research : Gann.

[36]  M. Lemmon,et al.  Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. , 1990, Cancer research.